文献速递胸部CT

切除的纯磨玻璃结节、异质性磨玻璃结节和部分实性肺结节的临床结局

Clinical Outcomes of Resected Pure Ground-Glass, Heterogeneous Ground-Glass, and Part-Solid Pulmonary Nodules.
PubMed 文献 · AJR Am J Roentgenol · 2024-05-15

这项回顾性研究纳入2012年1月至2020年12月间因CT显示亚实性结节而切除肺腺癌的469例患者,由两位放射科医师将结节分类为纯磨玻璃结节、异质性磨玻璃结节或部分实性结节并比较临床结局。异质性磨玻璃结节的侵袭性腺癌频率和7年无复发生存率、总生存率更接近部分实性结节而非纯磨玻璃结节,提示对真正均匀的纯磨玻璃结节可监测,而对内部密度增高的磨玻璃结节即使无真正实性成分也应切除。

要点

  • 异质性磨玻璃结节定义为内部密度增高但不及肺血管致密的磨玻璃结节,部分实性结节定义为内部实性成分密度与肺血管一致。
  • 侵袭性腺癌频率:纯磨玻璃结节39.0%、异质性磨玻璃结节67.9%、部分实性结节75.7%,异质性磨玻璃结节与部分实性结节间P=.28。
  • 7年无复发生存率:纯磨玻璃结节97.7%、异质性磨玻璃结节82.0%、部分实性结节79.4%,异质性磨玻璃结节与部分实性结节间P=.40。

核心结论

  • 切除的纯磨玻璃结节临床结局极好,异质性磨玻璃结节结局相对较差且更接近部分实性结节;研究结果支持对真正均匀的纯磨玻璃结节进行监测,而对内部密度增高的磨玻璃结节即使无真正实性成分也应切除。

研究设计与样本

  • 回顾性研究,纳入469例患者(335例女性、134例男性;中位年龄68岁,IQR 62.5-73.5岁),于2012年1月至2020年12月间接受CT显示为亚实性结节的肺腺癌切除。

诊断标准与关键数值

  • 异质性磨玻璃结节定义为内部密度增高但不及肺血管致密的磨玻璃结节;部分实性结节定义为内部实性成分密度与肺血管一致。

临床应用与阅片要点

  • 作者认为,研究结果支持对真正均匀的纯磨玻璃结节进行监测,而对内部密度增高的磨玻璃结节即使无真正实性成分也应切除。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Increased (but not definitively solid) attenuation within pure ground-glass nodules (pGGNs) may indicate invasive adenocarcinoma and the need for resection rather than surveillance. OBJECTIVE. The purpose of this study was to compare the clinical outcomes among resected pGGNs, heterogeneous ground-glass nodules (GGNs), and part-solid nodules (PSNs). METHODS. This retrospective study included 469 patients (335 female patients and 134 male patients; median age, 68 years [IQR, 62.5-73.5 years]) who, between January 2012 and December 2020, underwent resection of lung adenocarcinoma that appeared as a subsolid nodule on CT. Two radiologists, using lung windows, independently classified each nodule as a pGGN, a heterogeneous GGN, or a PSN, resolving discrepancies through discussion. A heterogeneous GGN was defined as a GGN with internal increased attenuation not quite as dense as that of pulmonary vessels, and a PSN was defined as having an internal solid component with the same attenuation as that of the pulmonary vessels. Outcomes included pathologic diagnosis of invasive adenocarcinoma, 5-year recurrence rates (locoregional or distant), and recurrence-free survival (RFS) and overall survival (OS) over 7 years, as analyzed by Kaplan-Meier and Cox proportional hazards regression analyses, with censoring of patients with incomplete follow-up. RESULTS. Interobserver agreement for nodule type, expressed as a kappa coefficient, was 0.69. Using consensus assessments, 59 nodules were pGGNs, 109 were heterogeneous GGNs, and 301 were PSNs. The frequency of invasive adenocarcinoma was 39.0% in pGGNs, 67.9% in heterogeneous GGNs, and 75.7% in PSNs (for pGGNs vs heterogeneous GGNs, p < .001; for pGGNs vs PSNs, p < .001; and for heterogeneous GGNs vs PSNs, p = .28). The 5-year recurrence rate was 0.0% in patients with pGGNs, 6.3% in those with heterogeneous GGNs, and 10.8% in those with PSNs (for pGGNs vs heterogeneous GGNs, p = .06; for pGGNs vs PSNs, p = .02; and for heterogeneous GGNs vs PSNs, p = .18). At 7 years, RFS was 97.7% in patients with pGGNs, 82.0% in those with heterogeneous GGNs, and 79.4% in those with PSNs (for pGGNs vs heterogeneous GGNs, p = .02; for pGGNs vs PSNs, p = .006; and for heterogeneous GGNs vs PSNs, p = .40); OS was 98.0% in patients with pGGNs, 84.6% in those with heterogeneous GGNs, and 82.9% in those with PSNs (for pGGNs vs heterogeneous GGNs, p = .04; for pGGNs vs PSNs, p = .01; and for heterogeneous GGNs vs PSNs, p = .50). CONCLUSION. Resected pGGNs had excellent clinical outcomes. Heterogeneous GGNs had relatively worse outcomes, more closely resembling outcomes for PSNs. CLINICAL IMPACT. The findings support surveillance for truly homogeneous pGGNs versus resection for GGNs showing internal increased attenuation even if not having a true solid component.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Sun JD, Sugarbaker E, Byrne SC, et al. Clinical Outcomes of Resected Pure Ground-Glass, Heterogeneous Ground-Glass, and Part-Solid Pulmonary Nodules. AJR Am J Roentgenol. 2024. PMID: 38323785. doi:10.2214/AJR.23.30504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。